{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:47:16Z","timestamp":1791787636301,"version":"4.3.4"},"reference-count":11,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.idnow.2026.105361","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:04:01Z","timestamp":1791270241000},"page":"105361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of pretreatment HBs-Ag levels on response to interferon therapy in chronic hepatitis D patients"],"prefix":"10.1016","volume":"56","author":[{"given":"Salih","family":"K\u0131l\u0131\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-7710","authenticated-orcid":false,"given":"Ahmed","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Yaln\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim","family":"Halil Bah\u00e7ecio\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.idnow.2026.105361_bb0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13099-021-00462-0","article-title":"Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis","volume":"13","author":"Chen","year":"2021","journal-title":"Gut Pathog"},{"issue":"8","key":"10.1016\/j.idnow.2026.105361_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/v14081749","article-title":"A review of HDV infection","volume":"14","author":"Caviglia","year":"2022","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/j.idnow.2026.105361_bb0015","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.3748\/wjg.v27.i24.3530","article-title":"Hepatitis delta virus: from infection to new therapeutic strategies","volume":"27","author":"Niro","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.idnow.2026.105361_bb0020","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.idnow.2026.105361_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idnow.2026.105361_bb0030","unstructured":"European Medicines Agency [Internet]. n.d. Hepcludex (bulevirtide) - Summary of Product Characteristics [cited October 4, 2026]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex."},{"issue":"2","key":"10.1016\/j.idnow.2026.105361_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.idnow.2026.105361_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with Pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.idnow.2026.105361_bb0045","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1038\/s41598-020-64122-0","article-title":"Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg","volume":"10","author":"Shekhtman","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.idnow.2026.105361_bb0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/135965350701200307","article-title":"Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring","volume":"12","author":"Manesis","year":"2007","journal-title":"Antivir Ther"},{"issue":"7","key":"10.1016\/j.idnow.2026.105361_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102148","article-title":"Chronic hepatitis delta cirrhosis cured by adapting PEG-IFN\u03b1-2a + tenofovir disoproxil fumarate treatment duration until HBsAg loss","volume":"47","author":"Yaici","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926001181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926001181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:18:03Z","timestamp":1791785883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991926001181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666991926001181"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105361","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of pretreatment HBs-Ag levels on response to interferon therapy in chronic hepatitis D patients","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105361"}}